GlassScriptPhysician profile
Amanda A Ward
NPI 1164816906
$309.93
in general payments reported to CMS, 2019-2025
11 companies · $41.09 in 2025
The $41.09 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $177 · 2022: $92.28 · 2025: $41.09.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $41.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $41.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $64.25 | 2022 | |
| Genzyme Corporation | $41.09 | 2025 | |
| Biogen, INC. | $37.14 | 2021 | |
| Sunovion Pharmaceuticals INC. | $31.85 | 2021 | |
| Daiichi Sankyo INC. | $28.03 | 2022 | |
| Lilly USA, LLC | $25.37 | 2021 | |
| Quidel Corporation | $24.27 | 2021 | |
| Tris Pharma INC | $19.70 | 2021 | |
| Abbvie INC. | $14.03 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $12.49 | 2021 | |
| Adlon Therapeutics L.P. | $11.71 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.